Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer

Clinical Lung Cancer

Volumn 3, Issue 1, 2001, Pages 49-57

  Palmer, Martin ^a   Parker, Joanne ^b   Modi, Shanu ^a   Butts, Charlie ^a   Smylie, Mike ^a   Meikle, Allison ^b   Kehoe, Mairead ^b   MacLean, Grant ^b   Longenecker, Mike ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Biomira Inc   (Canada)

Author keywords

Active specific immunotherapy; Antibody production; Cytotoxic T lymphocytes; Liposomes; MUC1 vaccines

Indexed keywords

BLP 25; CYCLOPHOSPHAMIDE; LIPOSOME; MUCIN; MUCINOUS CARCINOMA ASSOCIATED GLYCOPROTEIN; ONDANSETRON; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EVALUATION; FEMALE; HELPER CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; INJECTION SITE; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MALE; NONHUMAN; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; SURVIVAL TIME; TUMOR CELL LINE; VACCINATION; VOMITING;

EID: 0034789572     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2001.n.018     Document Type: Article

References (42)

1. Chemotherapy of lung cancer
2. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial
3. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
4. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: Effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene
5. Heterogeneity of mucin gene expression in normal and neoplastic tissues
6. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients
7. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin
8. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer
9. Altered expression of sialyl-Tn, Lewis antigens and carcinoembryonic antigen between primary and metastatic lesions of uterine cervical cancers
10. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin
11. MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats
12. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2
13. Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients
14. Tissue and tumour distribution of human polymorphic epithelial mucin
15. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine
16. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein
17. Clinical trials with MUC1-KLH and MUC2-KLH conjugate vaccines designed to induce an antibody response
18. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma
19. Systemic immunotherapy of advanced prostate cancer (CaP): Preliminary results of a phase I clinical trial using recombinant vaccina virus encoding human MUC-1 and interleukin-2 (IL-2) genes
20. Safety and therapeutic potential of a gene transfer approach in preclinical studies and in clinical trials in breast cancer patients using a recombinant pox virus
21. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide
22. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer
23. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role
24. Liposomal formulations of synthetic MUC1 peptides: Effects of encapsulation versus surface display of peptides on immune responses
25. Ovalbumin peptide encapsulated in poly(d,l lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response
26. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes
27. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses
28. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21
29. MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral
30. Effect of low dose cyclophosphamide on the immune system of cancer patients: Reduction of T-suppressor function without depletion of the CD8+ subset
31. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide
32. Effect of pre-existing cytotoxic T lymphocytes on therapeutic vaccines
33. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
34. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells
35. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA
36. Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls
37. Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells
38. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors
39. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
40. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy
41. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy
42. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine